Pancreatic cancer Overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. Pancreatic cancer occurs when changes (mutations) in the pancreas cells lead them to multiply out of control.
“Pancreatic cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pancreatic cancer Market.
The Pancreatic cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Pancreatic cancer Pipeline Report:
Companies across the globe are diligently working toward developing novel Pancreatic cancer treatment therapies with a considerable amount of success over the years. Pancreatic cancer Key players such as – Syntrix Biosystems, 4D pharma, Conjupro Biotherapeutics, Ampila Therapeutics, Helix BioPharma Corporation, Galera Therapeutics, ImmunityBio, NOXXON Pharma, AbbVie, FibroGen, and others, are developing therapies for the Pancreatic cancer treatment
Pancreatic cancer Emerging therapies such as – SX-682, MRx0518, CPO102, AMP945, L-DOS47, GC4711, N-803, NOX-A12, ABBV-927, Pamrevlumab, and others are expected to have a significant impact on the Pancreatic cancer market in the coming years.
In May 2021, AbbVie initiated a Phase I/II, randomized, controlled, open-label study evaluating the safety and efficacy of ABBV-927 administered in combination with modified FOLFIRINOX (mFFX) with or without budigalimab compared to mFFX in subjects with untreated metastatic Pancreatic Adenocarcinoma
Route of Administration
Pancreatic cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Products have been categorized under various Molecule types, such as
Pancreatic cancer Pipeline Therapeutics Assessment
Pancreatic cancer Assessment by Product Type
Pancreatic cancer By Stage and Product Type
Pancreatic cancer Assessment by Route of Administration
Pancreatic cancer By Stage and Route of Administration
Pancreatic cancer Assessment by Molecule Type
Pancreatic cancer by Stage and Molecule Type
DelveInsight’s Pancreatic cancer Report covers around 5+ products under different phases of clinical development like-
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Some of the key companies in the Pancreatic cancer Therapeutics Market include:
Key companies developing therapies for Pancreatic cancer are – Novartis AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, PharmaCyte Biotech, Inc., CLOVIS ONCOLOGY, CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd, and others.
Emerging Pancreatic cancer Drugs Under Different Phases of Clinical Development Include:
SX-682: Syntrix Biosystems
MRx0518: 4D pharma
CPO102: Conjupro Biotherapeutics
AMP945: Ampila Therapeutics
L-DOS47: Helix BioPharma Corporation
GC4711: Galera Therapeutics
NOX-A12: NOXXON Pharma
Get a Free Sample PDF Report to know more about Pancreatic cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight
Pancreatic cancer Pipeline Analysis:
The Pancreatic cancer pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Pancreatic cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic cancer Treatment.
Pancreatic cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Pancreatic cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic cancer market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Pancreatic cancer product details are provided in the report. Download the Pancreatic cancer pipeline report to learn more about the emerging Pancreatic cancer therapies
Pancreatic cancer Pipeline Market Drivers
Increase in Patient Burden
Development of Efficient Novel Treatments
Increasing healthcare expenditures
Pancreatic cancer Pipeline Market Barriers
Limited affordable technologies for timely diagnosis
Therapy options at the advanced stages are limited
Scope of Pancreatic cancer Pipeline Drug Insight
Key Pancreatic cancer Companies: Syntrix Biosystems, 4D pharma, Conjupro Biotherapeutics, Ampila Therapeutics, Helix BioPharma Corporation, Galera Therapeutics, ImmunityBio, NOXXON Pharma, AbbVie, FibroGen, and others
Key Pancreatic cancer Therapies: SX-682, MRx0518, CPO102, AMP945, L-DOS47, GC4711, N-803, NOX-A12, ABBV-927, Pamrevlumab, and others
Pancreatic cancer Therapeutic Assessment: Pancreatic cancer current marketed and Pancreatic cancer emerging therapies
Pancreatic cancer Market Dynamics: Pancreatic cancer market drivers and Pancreatic cancer market barriers
Request for Sample PDF Report for Pancreatic cancer Pipeline Assessment and clinical trials
Table of Contents
Pancreatic cancer Report Introduction
Pancreatic cancer Executive Summary
Pancreatic cancer Overview
Pancreatic cancer- Analytical Perspective In-depth Commercial Assessment
Pancreatic cancer Pipeline Therapeutics
Pancreatic cancer Late Stage Products (Phase II/III)
Pancreatic cancer Mid Stage Products (Phase II)
Pancreatic cancer Early Stage Products (Phase I)
Pancreatic cancer Preclinical Stage Products
Pancreatic cancer Therapeutics Assessment
Pancreatic cancer Inactive Products
Company-University Collaborations (Licensing/Partnering) Analysis
Pancreatic cancer Key Companies
Pancreatic cancer Key Products
Pancreatic cancer Unmet Needs
Pancreatic cancer Market Drivers and Barriers
Pancreatic cancer Future Perspectives and Conclusion
Pancreatic cancer Analyst Views
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Pancreatic cancer drugs and therapies
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States